Omeprazol Teva (Omeprazole)

Omeprazol Teva is a proton‑pump inhibitor that acts on gastric acid secretion pathways. It is indicated for several acid‑related gastrointestinal conditions:

• Gastroesophageal reflux disease (GERD): alleviates heart‑burn and esophageal irritation.
• Peptic ulcer disease: promotes healing of gastric and duodenal ulcers.
• Helicobacter pylori eradication regimens: used in combination with antibiotics to eradicate infection.
• Zoll‑Zollinger‑Ellison syndrome (ZES): controls excessive acid production associated with gastrin‑producing tumors.
• Acid‑related discomfort post‑operatively or from NSAID use: reduces risk of ulcer formation.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid secretion, it markedly lowers gastric acidity, allowing mucosal healing and symptom relief in acid‑related disorders.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis, angioedema).
• Clostridioides difficile‑associated colitis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Bone fracture risk with long‑term therapy.
• Acute interstitial nephritis.
• Liver enzyme elevation.

When prescribing Omeprazol Teva, clinicians should consider several safety aspects:

• Renal or hepatic impairment: adjust monitoring as needed.
• Long‑term use: assess need periodically to avoid unnecessary exposure.
• Concomitant use with clopidogrel: evaluate benefit‑risk balance.
• Pregnancy or lactation: use only if clearly needed.
• Elderly patients: monitor for falls related to possible hypomagnesemia.

Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atazanavir or other protease inhibitors: markedly reduced antiviral efficacy.
• Warfarin: potential increase in INR, requiring closer monitoring.

Moderate Interactions (Monitor Closely)

• Methotrexate: increased serum levels, especially with high‑dose regimens.
• Digoxin: modest rise in serum concentration.
• Diazepam: possible increase in sedation.
• Iron supplements: decreased absorption, separate dosing by at least 2 h.